Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Placebo Hepatitis Virus Infection" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Placebo Hepatitis Virus Infection for you to read. Along with our medical data and news we also list Placebo Hepatitis Virus Infection Clinical Trials, which are updated daily. BioPortfolio also has a large database of Placebo Hepatitis Virus Infection Companies for you to search.
Hepatitis C virus (HCV) is a small, enveloped virus comprising an RNA genome encased in a protein capsid and surrounded by a lipid bilayer containing two glycoproteins. Acute infection can cause hepatitis but the virus usually persists as a chronic infection of the liver where it can cause inflammation and, eventually, hepatocellular carcinoma. How HCV subverts hepatocytes to turn them into virus-...
Comparing the immune responses to and immunopathogenesis of infection with hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV) provides insight into the distinct outcomes of each type of viral hepatitis.
In The Lancet Infectious Diseases, Shevanthi Nayagam and colleagues1 report a modelling study on the effectiveness of different interventions on the incidence and mortality rate of chronic hepatitis B virus (HBV) infection. To appreciate the implications of this report, we need to understand the context. Chronic viral hepatitis is the seventh leading cause of death worldwide.2 Chronic HBV infectio...
Eiger BioPharmaceuticals Inc. announced it licensed pegylated interferon lambda-1a to Bristol-Myers Squibb to investigate the efficacy and safety of the drug as a therapeutic option for the treatment of hepatitis delta virus infection.Eiger plans to evaluate lambda, a type 3 interferon, as a potential monotherapy and combination regimen for individuals with chronic hepatitis delta virus (HDV) infe...
A novel investigation into the North American spread of hepatitis C virus permits blame shifting, which the authors Jeffrey Joy and colleagues hope will increase the number of baby boomers who undergo testing.1 The medical community can now take its share of the responsibility for hepatitis C virus infection in its conversations with the 1945–65 birth cohort. Joy and colleagues offer evidence th...
WEDNESDAY, April 13, 2016 -- Hepatitis C may increase the risk for certain types of head and neck cancers, researchers say. Hepatitis C is a serious liver infection caused by a virus. It's the most common bloodborne infection in the United States,...
(Wiley) Long-term infection with hepatitis B virus (HBV) can cause liver inflammation and increase the risk of liver cancer. Researchers from the US Centers for Disease Control and Prevention, however, found that resolving HBV infection was not associated with reduced rates of liver cancer.
Investigators have discovered how hepatitis A virus causes liver injury as well as how the virus could jump from primates to mice. Hepatitis A virus is a vaccine preventable form of infectious hepatitis. HAV is found worldwide and is transmitted through ingestion of food and water that is contaminated with the feces of an infected person.
Two new combination therapies that have the potential to cure patients with long-term hepatitis C virus infection and rule out the need for interferon are being recommended for approval across the EU.
Roche announced recently that it has received approval from the U.S. Food and Drug Administration (FDA) for its hepatitis C virus (HCV) quantitative RNA test to be used as an aid in the diagnosis of HCV infection for certain patient populations.
The US Food and Drug Administration (FDA) has approved Gilead Sciences’ Epclusa to treat adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.
A community-based hepatitis B virus screening effort led by UC Davis researchers found that targeted outreach to Asian American populations can identify groups at high risk for infection and direct them to appropriate follow-up care to help prevent the onset of liver diseases, including cancer. Published online today in Public Health Reports, the
Alnylam Pharmaceuticals Inc. announced the initiation of its phase 1/2 clinical trial with ALN-HBV, a subcutaneously administered investigational RNA-interference therapeutic for the treatment of chronic hepatitis B virus infection. The trial will first be conducted on healthy volunteers, then in patients with chronic hepatitis B virus. It is based on encouraging pre-clinical data presented at the...
The post FDA approves Epclusa for treatment of chronic Hepatitis C virus infection – FDA.gov appeared first on LifeSciences Healthcare.
It is estimated that one in 30 baby boomers have hepatitis C virus infection and one in 12 Asian Americans and Pacific Islanders have hepatitis B virus infection. Still, a majority of the infected people in these at-risk populations are not aware of their infection. To raise awareness of these and other at-risk populations — including injection drug users and recipients of transfusions — the C...
In this Viewpoint, 2016 Lasker Award winners Ralf Bartenschlager, Charles Rice, and Michael Sofia discuss their work developing a system to study the replication of hepatitis C virus and a class of antivirals to treat the infection.
The European Medicines Agency (EMA) has recommended the approval of marketing authorisations for two latest combination therapies against chronic (long-term) hepatitis C virus (HCV) infection in the European Union (EU).
The survival rate of patients with hepatitis C virus-related cirrhosis who respond well to antiviral therapies equals that of the general population, say investigators in the Journal of Hepatology. Long-term development of cirrhosis and liver disorders, such as decompensation or hepatocellular carcinoma, after infection with hepatitis C virus
BARCELONA — In an ongoing phase 1b clinical trial, NVR 3-778, a hepatitis B virus core inhibitor, safely reduced HBV DNA levels in patients with chronic hepatitis B virus infection, according to a Late Breaker presentation at International Liver Congress.“There is no formal name for this medication, but it is a first-in-class inhibitor,” Man-Fung Yuen, MBBS, MD, PhD, chair and professor of g...
Individuals who are current excessive alcohol drinkers or are former drinkers are more likely to have hepatitis C virus infection and an increased risk for further liver damage vs. abstainers and nonexcessive drinkers, according to published findings. “Half of all people living with hepatitis C are not aware of their infection nor the serious medical risks they face when consuming alcohol,” Am...
A new study finds that the risk of developing liver cancer from infection with hepatitis B persists even after patients have apparently been cleared of the virus.
The current standard in diagnosing Hepatitis C virus (HCV) infection requires two sequential steps that make it suboptimal, costly, inconvenient,...
Hepatitis B virus (HBV) causes hepatitis B, an infectious disease that afflicts 230 million people worldwide, thereof 440 000 in Germany. Persistence of the virus in liver cells leads to progressive organ damage in the patient and contributes to a high risk of cirrhosis and liver cancer development....
Hepatitis researchers have long thought that immune cells sent by the body to attack virus-infected cells in the liver cause the acute liver injury associated with hepatitis A virus (HAV) and other hepatitis viruses. Yet, investigators at the University of North Carolina at Chapel Hill have discovered that it is an immediate, intrinsic response of
Sound health policy puts patients first. Antiviral regimens approved in 2014 revolutionised treatment of hepatitis C virus (HCV) infection. Most patients can now be cured. These new regimens, however, were priced at US$83 320–150 000 for a 3-month course. Public and private payers in the USA responded by limiting coverage to patients with advanced fibrosis or cirrhosis, keeping the drugs fro...